The EMA recommended adding NAION to the product information (similar to the drugs warning label)
This includes incorporating plenty of lean proteins, fiber-rich vegetables, and complex carbohydrates that support stable blood sugar levels
Key gaps No semaglutide trial programme publicly reports validated vaginal symptom patient-reported outcomes (dryness scales, dyspareunia scores, pH/microbiome endpoints) in regulatory product information, limiting incidence estimation for vaginal endpoints
Changes in other parameters, such as glycemic control, body weight, blood pressure, and lipid profile, favored dulaglutide over placebo
Bracesco, N., Snchez, A
Safety and Efficacy of Glutathione in Dermatology